Telixpharma
telixpharma.com
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Financials
Overview
Telix is a global, commercial-stage biopharmaceutical company focused on the development of diagnostic and therapeutic (‘theranostic’) products using targeted radiation.
News
Telix to Host R&D Day in New York City on September 22, 2026
Telix to Host R&D Day in New York City on September 22, 2026 Melbourne (Australia) and Indianapolis, IN (United States) August 5, 2026 Telix today advises that it will host a Research and Development (R&D) Day on Tuesday, September 22, 2026, from 8:30 a.m
Read more
Report
Telix H1 2026 Results: Investor Webcast Notification
Telix H1 2026 Results: Investor Webcast Notification Melbourne (Australia) and Indianapolis, IN (United States) July 31, 2026 Telix today advises that it will release its financial results for the half-year ended June 30, 2026 on Thursday August 20, 2026.
Read more
Report
EJNMMI Research: TLX400-Tx Shows Encouraging Disease Control in Medullary Thyroid Cancer
EJNMMI Research: TLX400-Tx Shows Encouraging Disease Control in Medullary Thyroid Cancer Melbourne (Australia) and Indianapolis, IN (United States) July 24, 2026 Telix today announces publication of long-term clinical outcomes from an investigator-led stu
Read more
Report
TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
TLX591-Tx ProstACT SELECT Study Published in Cancers Journal Melbourne (Australia) and Indianapolis, IN (United States) July 22, 2026 Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select pa
Read more
Report
Pro access
Upgrade to see all 11 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
Growth
Hiring Momentum
28/100
Slowing
Open positions
0
0 opened / 0 closed in 30 days
Hiring Dynamics
0%